share_log

Krystal Biotech Announces Initial Results From Ongoing KYANITE-1 Study Of KB707; Observed 27% Objective Response Rate And 73% Disease Control Rate As Of Data Cut-Off On Dec. 6

Krystal Biotech Announces Initial Results From Ongoing KYANITE-1 Study Of KB707; Observed 27% Objective Response Rate And 73% Disease Control Rate As Of Data Cut-Off On Dec. 6

Krystal Biotech宣佈KB707的KYANITE-1研究的初步結果;截至12月6日的數據截止,觀察到27%的客觀反應率和73%的疾病控制率。
Benzinga ·  12/18 21:06

Krystal Biotech Announces Initial Results From Ongoing KYANITE-1 Study Of KB707; Observed 27% Objective Response Rate And 73% Disease Control Rate As Of Data Cut-Off On Dec. 6

Krystal Biotech宣佈KB707的KYANITE-1研究的初步結果;截至12月6日的數據截止,觀察到27%的客觀反應率和73%的疾病控制率。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論